A Phase II Study of Crizotinib in Patients with High-Risk Uveal Melanoma

Full Title

Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy


Uveal melanoma, a type of cancer that develops in the back of the eye, is usually treated with surgery or radiation therapy. About half of all uveal melanomas come back in another part of the body. In this study, researchers want to evaluate the safety and effectiveness of the drug crizotinib in patients with uveal melanomas that have been treated with surgery or radiation therapy but have a high risk of coming back.

Crizotinib is already approved for treating a type of lung cancer, but its use for uveal melanoma is considered investigational. Laboratory studies show that crizotinib can kill uveal melanoma cells. It is a pill that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have uveal melanoma determined to have a high risk of coming back after surgery or radiation therapy, as determined by a gene profile test.
  • Prior treatment must have been completed at least 3 weeks but no more than 90 days before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Alexander Shoushtari at 646-888-4161.